BPC-157 + TB-500 Blend 10mg

Each 10mg vial contains an equal-ratio combination of 5mg BPC-157 (sequence: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) and 5mg TB-500 (sequence: Ac-LKKTETQ). Researchers combine these two peptides because their mechanisms are thought to be complementary: BPC-157 acts via VEGFR2, nitric oxide, and FAK-paxillin pathway modulation; TB-500 acts primarily via actin-sequestering and cell migration promotion. By targeting different cellular pathways involved in tissue repair, the combination provides a broader research model than either compound alone. The blend format removes the need to prepare two separate vials, simplifying research protocols.

The blend reconstitutes identically to individual peptides. Draw 1–2mL of bacteriostatic water into a clean 31G syringe. Inject slowly down the inner glass wall of the vial. Gently swirl — do not shake or vortex — until the lyophilised powder is fully dissolved. The solution should be clear and colourless. With 1mL BAC water: each component is at 5mg/mL (BPC-157 5mg/mL + TB-500 5mg/mL). With 2mL: 2.5mg/mL each. Storage: Lyophilised at −20°C up to 24 months. Reconstituted at 2–8°C, use within 4 weeks, protected from light.

Legal status: Both BPC-157 and TB-500 are legal to purchase in Australia for laboratory research purposes. Neither is a scheduled substance under the Poisons Standard when sold for research use only. Not for human consumption, therapeutic, cosmetic, or veterinary use. Quality: Batch PW-260311, verified at 99.0% HPLC purity for the combined blend. Both components are independently quality-tested before blending. The COA covers: HPLC purity for each component, mass spectrometry identity confirmation (BPC-157: MW 1419.53 Da; TB-500: MW 895.08 Da), and sterility screening. Full COA available in our COA Library.

The blend is ideal when your research protocol uses both peptides at a 1:1 ratio — it simplifies preparation, reduces the number of vials to handle, and is more cost-effective than purchasing separately. If your research requires variable ratios of BPC-157 to TB-500 (e.g., 2:1, 1:2), or if you're studying each compound independently in separate assays, purchasing them separately gives more flexibility. We offer standalone BPC-157 10mg at /products/bpc-157-10mg and the blend — choose based on your specific research design.

TB-500 is a synthetic peptide fragment derived from thymosin beta-4 (Tβ4), a 43-amino acid protein. The active fragment commonly referred to as TB-500 has the sequence Ac-LKKTETQ (acetyl-Leu-Lys-Lys-Thr-Glu-Thr-Gln). Thymosin beta-4's primary mechanism involves sequestering G-actin (globular actin monomers), which regulates actin polymerisation dynamics and thereby influences cell migration, wound healing, and tissue remodelling. In preclinical research, TB-500 has been studied for promotion of endothelial and keratinocyte migration, cardiac tissue repair models, anti-inflammatory effects in muscle and connective tissue models, and systemic distribution to multiple tissue types. Not for human consumption — for research use only.

The TB-500 fragment (Ac-LKKTETQ) has a molecular weight of approximately 895.08 Da. Its full sequence is: Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln (N-terminally acetylated). CAS number for the Ac-LKKTETQ fragment: 77591-33-4. This fragment corresponds to residues 17–23 of thymosin beta-4, which is considered the actin-binding domain responsible for most of Tβ4's biological activity in cell migration and tissue repair research. Identity in our blend (Batch PW-260311) is confirmed by mass spectrometry as documented in the COA. Not for human consumption — for research use only.

The 1:1 (5mg:5mg) ratio is the most widely used combination ratio in published preclinical literature and represents the standard starting point for dual-peptide tissue repair research. It provides equal molar availability of both compounds (accounting for their different molecular weights — BPC-157 at 1419.53 Da and TB-500 at 895.08 Da, so 5mg each represents different molar quantities). The 1:1 ratio by mass provides a practical, reproducible benchmark. Researchers requiring different ratios for mechanistic studies should purchase BPC-157 10mg at /products/bpc-157-10mg and TB-500 separately to formulate custom ratios. Not for human consumption — for research use only.

Purchasing the blend vs. standalone BPC-157 10mg depends on your research design. The blend ($139.99) provides 5mg BPC-157 + 5mg TB-500 in a single vial — effectively two research compounds in one preparation at a lower combined cost than purchasing equivalent amounts separately. Standalone BPC-157 10mg ($89.99) at /products/bpc-157-10mg gives you the full 10mg of BPC-157 alone, with no TB-500 — appropriate for research protocols requiring only BPC-157, higher BPC-157 doses, or independent compound analysis. Not for human consumption — for research use only.

The CAS number for the TB-500 fragment (Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln, the active heptapeptide derived from thymosin beta-4) is 77591-33-4. Full thymosin beta-4 itself has CAS 61512-21-8. Our blend contains the TB-500 heptapeptide fragment at 5mg per vial, identity confirmed by mass spectrometry in the COA (Batch PW-260311). Not for human consumption — for research use only.

Both BPC-157 and TB-500 are independently confirmed in the Certificate of Analysis for Batch PW-260311 via: HPLC analysis showing separate retention time peaks for each component, confirming their individual presence and purity; and mass spectrometry confirming both molecular weights (BPC-157: 1419.53 Da; TB-500: 895.08 Da) in a single vial. The COA is publicly available in our COA Library. For researchers requiring additional identity verification, the reconstituted blend can be analysed independently using standard HPLC-MS with reference standards for each peptide. Not for human consumption — for research use only.

The blend's reconstituted stability is comparable to the individual peptides reconstituted separately. Both BPC-157 and TB-500 are stable in aqueous solution at 2–8°C for up to 4 weeks when reconstituted in bacteriostatic water. The presence of both peptides in the same solution does not produce known stability interactions — they are chemically distinct peptides that do not react with each other in solution. Standard handling applies: avoid freeze-thaw cycling of the reconstituted solution, protect from light, and label with reconstitution date. Not for human consumption — for research use only.

The rationale for combining BPC-157 and TB-500 is based on their complementary mechanisms identified in separate preclinical studies. BPC-157's documented effects via the NO/VEGFR2/FAK-paxillin pathways act at different cellular nodes than TB-500's actin-sequestering and cell migration-promoting activity. Published rodent studies on each compound individually in tendon, muscle, and wound healing models form the evidence base. While head-to-head combination studies in a single controlled model are limited in the published literature, the mechanistic complementarity and the breadth of individual compound data underpin the combination's use in complex tissue repair research protocols. Not for human consumption — for research use only.